Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \<40%
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
L-arginine 3 gm sachets are used twice daily
2 sachets of placebo are administered per day
Ain Shams University
Cairo, Egypt
Change of Global longitudinal strain value (GLS) of HF patients from the baseline
Time frame: 6 weeks
Change of heart failure symptoms as determined by NYHA classification from baseline
Time frame: 6 weeks
Change of the functional abilities (ECG) of the patients as determined by the exercise test from baseline
Time frame: 6 weeks
Changes in biomarkers of heart failure as determined by the difference in NT-proBNP levels from baseline
Time frame: 6 weeks
Change in quality of life between 2 groups as determined by Minnesota Living with Heart Failure questionnaire
Time frame: 6 weeks
Safety profile of the L-Arginine as determined by the change in the mean arterial pressure (MAP) between the 2 groups
Time frame: 6 weeks
Change in biomarkers of endothelial dysfunction as determined by the difference in levels of endothelin-1
Time frame: 6 weeks
Change in biomarkers of endothelial dysfunction as determined by the difference in levels of Asymmetric dimethylarginine (ADMA)
Time frame: 6 weeks
Safety profile of the L-Arginine as determined by the change in the heart rate (HR) between the 2 groups
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.